Custom-tailored extrapulmonary lung support - NEW: All iLA activve® Kits now have long-term approval for 29 days of use
(PresseBox) - The iLA activve® further extends its leadership as the only lung assist platform with a complete range of four differently sized iLA activve® Kits. Long term CE approval (29 days) for all iLA activve® Kits is another step forward for Novalung's allrounder that covers the full spectrum of extrapulmonary lung support in acute and acute-on-chronic lung failure.
Three years ago, Novalung successfully launched the pump-driven iLA activve® lung support system that enables the full range of established and evolving lung support therapies. The iLA activve® Kits all feature a Membrane Ventilator, our unique diagonal pump and complete tubing sets that match our novaport range of percutaneous long term cannulas.
In addition to the proven iLA Membrane Ventilator®, three additional highly efficient Membrane Ventilators have been available for use with the system since 2013: The MiniLung® petite Membrane Ventilator, MiniLung® Membrane Ventilator, iLA® Membrane Ventilator or XLung® Membrane Ventilator all feature the leading plasma-tight PMP membrane and the proven Novalung coating. They allow unique, custom-tailored therapies for adults, children and neonates. The iLA activve Kits for the Minilung and Minilung petuite are the first pediatric and neonatal ECMO kits worldwide with long term approval (CE).
The now available long-term approval for 29 days for all kits further expands the range of applications for targeted extrapulmonary lung support in adults, children and neonates.
Together with the recent technology updates of the iLA active console this step is part of our dedication to provide new solutions for lung failure: iLA activve® System Platform: From efficient carbon dioxide removal to complete oxygenation, iLA activve® is the allrounder for extrapulmonary lung support.
Novalung GmbH is a leading international medical device company with headquarters in Heilbronn, Germany. Novalung has been developing and manufacturing products for interventional lung assist (iLA®) therapy in Germany since 2003 and is today the first to offer a complete product portfolio for extrapulmonary lung support. Whatever form of extrapulmonary lung support is required, Novalung can offer the perfect solution, from effective removal of carbon dioxide to complete oxygenation support, for new-born infants through to adults. A broad technology base, extensive clinical experience, specialized know-how and outstanding motivation guarantee the consistently high quality of Novalung products. Working together with leading users, the company has continuously advanced Novalung's technologies to develop iLA® therapy as an alternative to invasive ventilation, and as such has initiated a paradigm shift in the treatment of lung failure.
Following a clear focus on the further development of iLA® therapy to pioneer novel solutions for acute and chronic lung failure, the company remains on track for continued expansion.
From our manufacturing sites across Germany we deliver solutions for lung failure throughout the world. For more information, please visit:
www.novalung.com.
Novalung GmbH is a leading international medical device company with headquarters in Heilbronn, Germany. Novalung has been developing and manufacturing products for interventional lung assist (iLA®) therapy in Germany since 2003 and is today the first to offer a complete product portfolio for extrapulmonary lung support. Whatever form of extrapulmonary lung support is required, Novalung can offer the perfect solution, from effective removal of carbon dioxide to complete oxygenation support, for new-born infants through to adults. A broad technology base, extensive clinical experience, specialized know-how and outstanding motivation guarantee the consistently high quality of Novalung products. Working together with leading users, the company has continuously advanced Novalung's technologies to develop iLA® therapy as an alternative to invasive ventilation, and as such has initiated a paradigm shift in the treatment of lung failure.
Following a clear focus on the further development of iLA® therapy to pioneer novel solutions for acute and chronic lung failure, the company remains on track for continued expansion.
From our manufacturing sites across Germany we deliver solutions for lung failure throughout the world. For more information, please visit:
www.novalung.com.
Datum: 02.10.2014 - 14:43 Uhr
Sprache: Deutsch
News-ID 340789
Anzahl Zeichen: 3234
contact information:
Town:
Heilbronn
Kategorie:
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Custom-tailored extrapulmonary lung support - NEW: All iLA activve® Kits now have long-term approval for 29 days of use"
steht unter der journalistisch-redaktionellen Verantwortung von
Novalung GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
